Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium

Julianne Byrne, Irene Schmidtmann, Humayra Rashid, Oskar Hagberg, Francesca Bagnasco, Edit Bardi, Florent De Vathaire, Samira Essiaf, Jeanette Falck Winther, Eva Frey, Thorgerdur Gudmundsdottir, Riccardo Haupt, Michael M. Hawkins, Zsuzsanna Jakab, Momcilo Jankovic, Peter Kaatsch, Leontien C.M. Kremer, Claudia E. Kuehni, Arja Harila-Saari, Gill LevittRaoul Reulen, Cécile M. Ronckers, Milena Maule, Roderick Skinner, Eva Steliarova-Foucher, Monica Terenziani, Lorna Zadravec Zaletel, Lars Hjorth, Stanislaw Garwicz, Desiree Grabow

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

2 Citaten (Scopus)

Samenvatting

Late mortality of European 5-year survivors of childhood or adolescent cancer has dropped over the last 60 years, but excess mortality persists. There is little information concerning secular trends in cause-specific mortality among older European survivors. PanCareSurFup pooled data from 12 cancer registries and clinics in 11 European countries from 77 423 five-year survivors of cancer diagnosed before age 21 between 1940 and 2008 followed for an average age of 21 years and a total of 1.27 million person-years to determine their risk of death using cumulative mortality, standardized mortality ratios (SMR), absolute excess risks (AER), and multivariable proportional hazards regression analyses. At the end of follow-up 9166 survivors (11.8%) had died compared to 927 expected (SMR 9.89, 95% confidence interval [95% CI] 9.69-10.09), AER 6.47 per 1000 person-years, (95% CI 6.32-6.62). At 60 to 68 years of attained age all-cause mortality was still higher than expected (SMR = 2.41, 95% CI 1.90-3.02). Overall cumulative mortality at 25 years from diagnosis dropped from 18.4% (95% CI 16.5-20.4) to 7.3% (95% CI 6.7-8.0) over the observation period. Compared to the diagnosis period 1960 to 1969, the mortality hazard ratio declined for first neoplasms (P for trend <.0001) and for infections (P <.0001); declines in relative mortality from second neoplasms and cardiovascular causes were less pronounced (P =.1105 and P =.0829, respectively). PanCareSurFup is the largest study with the longest follow-up of late mortality among European childhood and adolescent cancer 5-year survivors, and documents significant mortality declines among European survivors into modern eras. However, continuing excess mortality highlights survivors' long-term care needs.

Originele taal-2Engels
Pagina's (van-tot)406-419
Aantal pagina's14
TijdschriftInternational Journal of Cancer
Volume150
Nummer van het tijdschrift3
DOI's
StatusGepubliceerd - 1 feb. 2022

Vingerafdruk

Duik in de onderzoeksthema's van 'Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium'. Samen vormen ze een unieke vingerafdruk.

Citeer dit